Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Long-Term Extension Study of Imsidolimab in Generalized Pustular Psoriasis
2021-001448-90Phase 3Terminated
- Sponsor
- AnaptysBio, Inc.
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of imsidolimab in generalized pustular psoriasis (GPP) and pustular psoriasis, sponsored by AnaptysBio, Inc. Primary endpoints: Incidence of adverse events and Long-term safety profile. Started Sep 2021; status: terminated.
02
Drugs
imsidolimab
03
Conditions
generalized pustular psoriasis (GPP)pustular psoriasis
Beyond the preview
Go deeper on 2021-001448-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001448-90.